Medtronic launches Penditure LAA exclusion system in the United States
Medtronic announced the United States launch of the Penditure left atrial appendage (LAA) exclusion system, an implantable clip preloaded on a single-use delivery system for LAA management during concomitant cardiac surgery procedures
The American College of Cardiology, American Heart Association, and Society of Thoracic Surgeons guidelines recommend that patients with preoperative atrial fibrillation undergoing concomitant cardiac surgery should have their LAA closed to reduce stroke risk.
According to the company, the Penditure clip is curved to match atrial anatomy and does not include fabric for atraumatic closure and reduced inflammation. It is designed to be recaptured, repositioned, and redeployed after initial deployment during a procedure.
Medtronic acquired the device technology from Syntheon LLC in August 2023 to expand its cardiac surgery profile to include LAA management.
The Penditure LAA Exclusion System received a 510k clearance in August 2023 and is commercially available in the US on a limited basis at this time.
Related news and insights
RAPT Therapeutics, Inc. announced that the FDA has verbally notified the company that a clinical hold has been placed on the company’s Phase IIb trial of zelnecirnon (RPT193) in atopic dermatitis and its Phase IIa trial in asthma
Bristol Myers Squibb announced that the FDA has accepted for priority review the supplemental new drug application (sNDA) for Krazati (adagrasib) in combination with cetuximab for the treatment of patients with previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC)
Tenax Therapeutics, Inc., a Phase III, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced it has secured global development, commercial, and IP rights to oral and subcutaneous levosimendan for the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)